Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens

Abstract

During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various disorders, such as major depressive disorder (MDD). However, the non-medical use of these substances became rampant due to their hallucinogenic effects, leading to their classification as narcotics in numerous countries by the 1970s. Since the 1990s, clinical research has resumed. Recently, powerful and rapid therapeutic effects, not observed with conventional psychotropic drugs, have been discovered, garnering global attention. In addition, clinical research in recent years has led to various clinical trials being conducted in the hope of using psychedelics as therapeutic drugs. Specifically, research is beginning to show that cannabidiol, ketamine, MDMA, and psilocybin, the main ingredient in "magic mushrooms," are effective for depression and post-traumatic stress disorder. In particular, patients with postpartum depression and premenstrual dysphoric disorder (PMDD) may benefit. Marijuana derives from cannabis, a plant that has its origin in Central Asia. It has been used for ceremonial and medicinal purposes